Does Tirzepatide Increase Cancer Risk in People With Diabetes?
A meta-analysis of 9 clinical trials found no increased cancer risk with tirzepatide, but the studies were too short to be definitive.
Quick Facts
What This Study Found
Across all 9 trials, tirzepatide did not increase the risk of cancer overall or any specific cancer type. This held true regardless of what the comparison drug was.
However, the authors stress this is preliminary. The trials were short (36 to 72 weeks), which is not long enough to detect most drug-related cancer signals. Cancer takes years to develop, and these studies were designed to measure diabetes outcomes, not cancer risk.
Key Numbers
- 9 randomized controlled trials included
- Study durations: 36 to 72 weeks
- No significant increase in risk for any cancer type or overall cancer
- Small number of total cancer events across all trials (exact count not stated)
How They Did This
The researchers conducted a meta-analysis of all available phase 2 and phase 3 randomized controlled trials evaluating tirzepatide in type 2 diabetes, published up to April 2024. They pooled data from 9 trials. The primary endpoint was risk of any cancer. Secondary endpoints covered specific cancer types. Subgroup analyses looked at different comparator drugs.
Why This Research Matters
Any new widely-prescribed drug needs cancer safety data. Tirzepatide is being used by millions for diabetes and weight loss. Previous GLP-1 drugs raised early concerns about pancreatic and thyroid cancers that were largely not confirmed in longer studies. This meta-analysis provides early reassurance for tirzepatide, though longer follow-up is essential.
The Bigger Picture
Previous GLP-1 drugs raised early concerns about pancreatic and thyroid cancers that were largely not confirmed in longer studies. This meta-analysis provides early reassurance for tirzepatide, but longer follow-up is essential.
What This Study Doesn't Tell Us
The biggest limitation is time. Cancer typically develops over years, and these trials lasted only 36 to 72 weeks. The number of cancer events was small, reducing statistical power. The trials were not designed to detect cancer as a primary outcome. This is hypothesis-generating, not definitive.
Questions This Raises
- ?Will longer-term studies reveal a cancer signal that short trials missed?
- ?Does the GIP component of tirzepatide have different cancer implications than GLP-1 alone?
Trust & Context
- Key Stat:
- No increased cancer risk Across 9 randomized controlled trials lasting 36–72 weeks, tirzepatide showed no increase in any cancer type
- Evidence Grade:
- Rated moderate: meta-analysis of randomized trials provides good methodology, but trial durations were too short and cancer events too few for definitive conclusions.
- Study Age:
- Published in 2024 analyzing trials through April 2024. Tirzepatide was only approved in 2022, so long-term data is naturally limited.
- Original Title:
- Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
- Published In:
- Diabetes research and clinical practice, 213, 111758 (2024)
- Authors:
- Popovic, Djordje S(7), Patoulias, Dimitrios(10), Popovic, Lazar S, Karakasis, Paschalis, Papanas, Nikolaos, Mantzoros, Christos S
- Database ID:
- RPEP-09082
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
Does tirzepatide cause cancer?
Current evidence from 9 clinical trials shows no increased cancer risk, but the studies were short (under 72 weeks) and cancer takes years to develop.
Should I worry about cancer while taking tirzepatide?
The early data is reassuring, but long-term monitoring continues. No drug-related cancer signal has emerged, consistent with the GLP-1 drug class overall.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09082APA
Popovic, Djordje S; Patoulias, Dimitrios; Popovic, Lazar S; Karakasis, Paschalis; Papanas, Nikolaos; Mantzoros, Christos S. (2024). Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.. Diabetes research and clinical practice, 213, 111758. https://doi.org/10.1016/j.diabres.2024.111758
MLA
Popovic, Djordje S, et al. "Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.." Diabetes research and clinical practice, 2024. https://doi.org/10.1016/j.diabres.2024.111758
RethinkPeptides
RethinkPeptides Research Database. "Tirzepatide use and the risk of cancer among individuals wit..." RPEP-09082. Retrieved from https://rethinkpeptides.com/research/popovic-2024-tirzepatide-use-and-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.